The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.85
Bid: 0.80
Ask: 0.90
Change: 0.025 (3.03%)
Spread: 0.10 (12.50%)
Open: 0.81
High: 0.85
Low: 0.80
Prev. Close: 0.825
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Dec 2017 08:27

RNS Number : 3872Z
N4 Pharma PLC
18 December 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

N4 PHARMA PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

X

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

NIGEL JAMES THEOBALD

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 DECEMBER 2017

6. Date on which issuer notified:

18 DECEMBER 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

16%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BYW8QM32

12,255,233

12,255,233

12,255,233

12,255,233

15.96%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

12,255,233

15.96%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

The Company's issued share capital increased on 18 December 2017 as a result of an exercise of warrants

14. Contact name:

Nigel Theobald

15. Contact telephone number:

+ 44 1332 690061

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFELFALSLID
Date   Source Headline
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update
15th Jul 20227:00 amRNSWork Programme Update
13th Jun 20227:00 amRNSWork Programme Update
24th Mar 202211:32 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.